- About Pancreatic Cancer
- Get Support
Caregivers
- Get Involved
- Events
- More
2023-11-28
2027-12
2027-12
300
NCT05824403
University Hospital, Toulouse
University Hospital, Toulouse
OBSERVATIONAL
PAncreatic Disease Cohort of TOuLouse
This study is a prospective cohort dedicated to pancreatic diseases excluding cancer. The aim is to develop positive or differential diagnostic tools between benign potentially malignant or malignant pancreatic pathologies. During this study the investigators collect data and biological samples to support research project.
This collection focuses on pathology of the pancreas requiring specific investigations or management for diagnosis or treatment. Pancreatic pathologies can be classified as malignant, potentially malignant or benign tumors. These can be solid or cystic. There is an inflammatory attack on the pancreas, generating acute pancreatitis in the acute period, if the inflammatory manifestations persist, chronic pancreatitis will develop. Some lesions may be at risk of malignancy during their evolution, it is therefore necessary to improve the performance of monitoring and diagnostic tools in order to adapt the management of patients.
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
| Study Registration Dates | Results Reporting Dates | Study Record Updates |
|---|---|---|
2023-03-27 | N/A | 2023-11-28 |
2023-04-19 | N/A | 2023-12-04 |
2023-04-21 | N/A | 2023-11 |
This section provides details of the study plan, including how the study is designed and what the study is measuring.
Primary Purpose:
N/A
Allocation:
N/A
Interventional Model:
N/A
Masking:
N/A
Arms and Interventions
| Participant Group/Arm | Intervention/Treatment |
|---|
| Primary Outcome Measures | Measure Description | Time Frame |
|---|---|---|
| Diagnostic tools | To develop positive or differential diagnostic tools between benign potentially malignant or malignant pancreatic pathologies | 3 years after the first inclusion |
| Secondary Outcome Measures | Measure Description | Time Frame |
|---|---|---|
| New targets | To identify new screening targets | 3 years after the first inclusion |
| Improvement of management | To improve the management of cystic lesions or Chronic pancreatitis on the decision of therapeutic management | 3 years after the first inclusion |
| Microbiota | Study of the microbiota of pancreatic diseases | 3 years after the first inclusion |
| Clinical data access | To make available to the scientific community quality material with associated clinical data also of quality | 3 years after the first inclusion |
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
|
Study Contact Name: Barbara BOURNET, MD Phone Number: 0561323235 Email: bournet.b@chu-toulouse.fr |
Study Contact Backup Name: Cindy CANIVET Phone Number: 05 61 32 20 48 Email: canivet.c@chu-toulouse.fr |
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.
Ages Eligible for Study:
ALL
Sexes Eligible for Study:
18 Years
Accepts Healthy Volunteers:
This is where you will find people and organizations involved with this study.
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
